| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:2465-2471.)
© 1996 American Heart Association, Inc.
Articles |
Lanreotide Reduces Serum Free and Total Insulin-Like Growth Factor-I After Angioplasty
the Institute of Experimental Clinical Research, Aarhus (Denmark) University Hospital, Kommunehospitalet (J.F., C.S., H.Ø.); IPSEN ApS, Copenhagen, Denmark (N.A.); the Department of Cardiology, Sahlgrenska Sjukhuset, Goteborg, Sweden (H.E.); the Department of Cardiology, Hospital de Weezenlanden, Zwolle, the Netherlands (H.S.); the Department of Cardiology, Waldkrankenhaus St. Marien, Erlangen, Germany (H.B.); and Georgetown University Medical Center and Henri Beaufour Institute-USA (M.F.).
Correspondence to Jan Frystyk, MD, Institute of Experimental Clinical Research, Aarhus Kommunehospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark.
Background Several experiments point to a participating role of insulin-like growth factor-I (IGF-I) in the vascular events leading to restenosis after percutaneous transluminal coronary angioplasty (PTCA).
Methods and Results We measured fasting serum total (extractable) IGF-I in 553 patients in a controlled clinical trial. Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA. We also measured ultrafiltrated serum free IGF-I and IGF-II, total IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and insulin in a subgroup of 18 placebo-treated and 20 lanreotide-treated patients. Total IGF-I had decreased by 7% (P<.0001) 1 day after initiation of lanreotide infusion and stayed reduced, whereas no early changes occurred in placebo-treated patients. The same pattern was observed in the subgroup. Free IGF-I decreased significantly from baseline by 22% to 27% (P<.05) in lanreotide-treated patients and increased insignificantly by 10% to 30% (P=.054) in placebo-treated patients. IGFBP-1 increased (P<.05) in both groups postoperatively, but levels in lanreotide-treated patients exceeded (P<.05) those of placebo-treated patients. Lanreotide treatment resulted in minor reductions (P<.05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered.
Conclusions Lanreotide administration acutely decreases circulating total and free IGF-I, the latter relatively more, and increases IGFBP-1. These alterations in the IGF system may participate in the improvement of the long-term outcome after PTCA noted with lanreotide treatment.
Key Words: growth substances • proteins • angiography • muscle, smooth
This article has been cited by other articles:
 |
|
 |
|
  R. J. Irving, M. N. Carson, D. J. Webb, and B. R. Walker Peripheral Vascular Structure and Function in Men with Contrasting GH Levels J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3309 - 3314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ruotolo, P. Bavenholm, K. Brismar, S. Efendic, C.-G.o. Ericsson, U. de Faire, J. Nilsson, and A. Hamsten Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment J. Am. Coll. Cardiol., March 1, 2000; 35(3): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frystyk, T. Grofte, C. Skjarbak, and H. Orskov The Effect of Oral Glucose on Serum Free Insulin-Like Growth Factor-I and -II in Healthy Adults J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3124 - 3127. [Abstract] [Full Text] [PDF]
|
|